U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.92 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Crude Oil

    83.98
    +0.22 (+0.26%)
     
  • Gold

    1,793.10
    -3.20 (-0.18%)
     
  • Silver

    24.39
    -0.06 (-0.24%)
     
  • EUR/USD

    1.1644
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3752
    -0.0044 (-0.32%)
     
  • USD/JPY

    113.5070
    -0.4810 (-0.42%)
     
  • BTC-USD

    60,953.57
    -318.46 (-0.52%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

Baxter's Norepinephrine Wins FDA Nod For Low Blood Pressure

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has approved Baxter International Inc's (NYSE: BAX) premix norepinephrine bitartrate in 5% dextrose injection.

  • Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).

  • According to a news release, the company's formulation of norepinephrine is the first and only manufacturer-prepared, ready-to-use formulation.

  • The Company offers the formulation in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.

  • Baxter's formulation has a shelf life of up to 21 months in a refrigerator or up to 90 days at room temperature in overwrap. It can be stored in automated dispensing cabinets at the point of care.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: BAX stock is up 0.12% at $81.15 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.